For research and educational purposes only. Not medical advice.

Maridebart Cafraglutide Reference

Educational, not medical advice reference for Maridebart Cafraglutide: GLP-1, Fat Loss, Metabolic; regulatory status, evidence posture, source r…

Reference summary

The Phase 1 first-in-human report (Veniant et al. 2024 Nature Metabolism) characterized single-dose pharmacokinetics, tolerability, and exploratory body-weight signals consistent with the monthly subcutaneous dosing rationale. The Phase 2 MARITIME readout via Amgen sponsor disclosure reported placebo-adjusted body-weight reductions over the trial period; detailed published methods and final analyses are pending peer-reviewed publication.

Regulatory and posture

Categories
GLP-1, Fat Loss, Metabolic
Aliases
MariTide, AMG 133, Amgen GLP-1R agonist + GIPR antagonist, Monthly subcutaneous antibody-peptide conjugate
Evidence posture
human - Investigational. The monthly cadence and GIP-antagonist (rather than agonist) arm differentiate this compound from the approved weekly GLP-1 / GIP agonist class. Phase 3 has not started. Do not present as available, approved, or compoundable.
Regulatory status
Investigational. Amgen's maridebart cafraglutide (MariTide / AMG 133) is an antibody-peptide conjugate combining a GLP-1 receptor agonist arm with a GIP receptor antagonist arm. There is no FDA-approved drug label. Phase 1 first-in-human results were published in Nature Metabolism in 2024 (Veniant et al.); Amgen's Phase 2 MARITIME program readout was reported via sponsor disclosure in late 2024 / 2025. Phase 3 has not started. Maridebart cafraglutide is not on FDA's approved bulk-substances list for traditional 503A compounding.
Content review status
investigational verified

Selected public sources

Related tools